黄曲霉毒素与胆囊癌的关联
基于上海胆道肿瘤病例对照研究(1997–2001年),209例胆囊癌合并胆结石患者与250例单纯胆结石对照相比,血浆黄曲霉毒素B1-赖氨酸加合物检出率更高(32% vs 15%),OR为2.71(95%CI 1.70-4.33)。54例胆囊癌肿瘤组织未检出TP53 R249S突变。黄曲霉毒素相关胆囊癌的人群归因分数为20%(95%CI 15%-25%)。
要点
- 胆囊癌患者血浆AFB1-赖氨酸加合物检出率32%(67/209),高于对照的15%(37/250),OR 2.71(95%CI 1.70-4.33)。
- AFB1-赖氨酸水平最高四分位组较最低四分位组胆囊癌OR为7.61(95%CI 2.01-28.84)。
- 54例胆囊癌肿瘤组织均未检出TP53 R249S突变,黄曲霉毒素相关人群归因分数为20%(95%CI 15%-25%)。
核心结论
- 在胆囊癌合并胆结石与单纯胆结石患者的病例对照研究中,基于血浆AFB1-赖氨酸水平的黄曲霉毒素暴露与胆囊癌相关。
- 胆囊癌似乎与TP53 R249S突变不相关。
- 若黄曲霉毒素是胆囊癌的病因,研究期间可能归因于高达20%的上海胆囊癌病例,在高风险地区比例可能更高。
- 若研究结果被验证,减少黄曲霉毒素暴露可能降低胆囊癌发病率。
研究设计与样本
- 研究类型为病例对照研究,基于1997年至2001年开展的上海胆道肿瘤病例对照研究。
- 比较209例胆囊癌合并胆结石患者与250例无癌的胆结石患者(对照)。
- 检测血浆AFB1-赖氨酸加合物,计算年龄和性别调整的OR及95%CI和人群归因分数。
- 对54例胆囊癌患者的肿瘤组织通过靶向测序检测TP53 R249S突变。
主要发现
- AFB1-赖氨酸加合物在209例胆囊癌患者中检出67例(32%),在250例对照中检出37例(15%),χ2 P<.0001。
- 胆囊癌患者检出AFB1-赖氨酸加合物的比值比为2.71(95%CI 1.70-4.33),约为对照的近三倍。
- 在可检出AFB1-赖氨酸的参与者中,胆囊癌患者中位水平为5.4 pg/mg,对照为1.2 pg/mg。
- AFB1-赖氨酸水平第四四分位组较第一四分位组胆囊癌OR为7.61(95%CI 2.01-28.84)。
- 54例测序的胆囊肿瘤均未发现TP53 R249S突变;黄曲霉毒素相关癌症的人群归因分数为20%(95%CI 15%-25%)。
关键数值与推荐
- 胆囊癌合并胆结石患者AFB1-赖氨酸加合物检出率为32%(67/209),单纯胆结石对照为15%(37/250),χ2 P<.0001。
- AFB1-赖氨酸加合物检出与胆囊癌的OR为2.71(95%CI 1.70-4.33)。
- AFB1-赖氨酸水平第四四分位组较第一四分位组胆囊癌OR为7.61(95%CI 2.01-28.84)。
- 黄曲霉毒素相关胆囊癌的人群归因分数为20%(95%CI 15%-25%)。
- 54例胆囊癌肿瘤组织中TP53 R249S突变检出0例。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文结论指出若研究结果被验证,减少黄曲霉毒素暴露可能降低胆囊癌发病率,提示需进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Aflatoxin, which causes hepatocellular carcinoma, may also cause gallbladder cancer. We investigated whether patients with gallbladder cancer have higher exposure to aflatoxin than patients with gallstones. METHODS: We measured aflatoxin B1 (AFB1)-lysine adducts in plasma samples from the Shanghai Biliary Tract Cancer case-control study, conducted from 1997 through 2001. We calculated age- and sex-adjusted odds ratios (ORs) and 95% confidence intervals (CIs) and the population-attributable fraction for 209 patients with gallbladder cancer and gallstones vs 250 patients with gallstones without cancer (controls). In 54 patients with gallbladder cancer, tumor tissue was examined for the R249S mutation in TP53, associated with aflatoxin exposure, through targeted sequencing. RESULTS: The AFB1-lysine adduct was detected in 67 (32%) of 209 patients with gallbladder cancer and 37 (15%) of the 250 controls (χ2 P < .0001), almost threefold more patients with gallbladder cancer than controls (OR, 2.71; 95% CI, 1.70-4.33). Among participants with detectable levels of AFB1-lysine, the median level of AFB1-lysine was 5.4 pg/mg in those with gallbladder cancer, compared with 1.2 pg/mg in controls. For patients in the fourth quartile of AFB1-lysine level vs the first quartile, the OR for gallbladder cancer was 7.61 (95% CI, 2.01-28.84). None of the 54 gallbladder tumors sequenced were found to have the R249S mutation in TP53. The population-attributable fraction for cancer related to aflatoxin was 20% (95% CI, 15%-25%). CONCLUSIONS: In a case-control study of patients with gallbladder cancer and gallstones vs patients with gallstones without cancer, we associated exposure to aflatoxin (based on plasma level of AFB1-lysine) with gallbladder cancer. Gallbladder cancer does not appear associate with the R249S mutation in TP53. If aflatoxin is a cause of gallbladder cancer, it may have accounted for up to 20% of the gallbladder cancers in Shanghai, China, during the study period, and could account for an even higher proportion in high-risk areas. If our findings are verified, reducing aflatoxin exposure might reduce the incidence of gallbladder cancer.
引用
- Koshiol J, Gao YT, Dean M, et al. Association of Aflatoxin and Gallbladder Cancer. Gastroenterology. 2017. PMID: 28428144. doi:10.1053/j.gastro.2017.04.005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。